Larimar Therapeutics (LRMR) Cash & Equivalents (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Cash & Equivalents for 14 consecutive years, with $92.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 350.22% year-over-year to $92.7 million; the trailing twelve-month figure through Jun 2026 stood at $92.7 million (up 350.22% YoY), and the FY2025 full-year result was $85.4 million, up 157.13% from the prior year.
• Cash & Equivalents climbed to $92.7 million in Q2 2026 per LRMR's latest filing, from $85.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $111.5 million in Q1 2023 and bottomed at $19.7 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $58.1 million across 5 years, with a median of $38.7 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents jumped 377.91% in 2023, then tumbled 80.82% in 2025.
• Over 5 years, Cash & Equivalents stood at $26.8 million in 2022, then decreased by 0.28% to $26.7 million in 2023, then gained by 24.18% to $33.2 million in 2024, then jumped by 157.13% to $85.4 million in 2025, then rose by 8.52% to $92.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $92.7 million, $85.4 million, and $90.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.